A growing number of lawsuits filed over the Paragard intrauterine device are products of plaintiffs’ attorney advertising, “not a genuine mass tort,” according Teva Pharmaceuticals USA Inc. and other defendants in the cases.
Teva and affiliated companies are fighting a bid to create multidistrict litigation for more than 55 lawsuits brought over the Paragard IUD, a birth control device that can break apart during surgical removal, leaving pieces in a woman’s uterus. In a Sept. 24 motion to transfer, filed before the U.S. Judicial Panel on Multidistrict Litigation, plaintiffs’ lawyers wrote that it was “likely that hundreds of other actions will be filed.”
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
